The GR20 monoclonal antibody specifically binds to CD119, the α chain of the interferon γ (IFN-γ) receptor. This receptor is expressed by mouse leukocytes, endothelial, and epithelial cells, but not by mature erythrocytes. GR20 mAb recognizes an epitope (susceptible to certain fixatives) in the ligand-binding site of the receptor. It can block the binding of mouse IFN-γ; therefore, it can inhibit IFN-γ .mediated effects including the activation of mouse macrophages for tumor cell killing. IFN-γ has been reported to induce the expression of Ly-6A/E antigen on cell lines and normal B lymphocytes, and the GR20 antibody is capable of inhibiting the IFN-γ.induced expression of Ly-6A/E on the mouse B lymphoma line A20. The binding of the GR20 antibody to CD119 is inhibited by IFN-γ. This antibody reportedly does not have any agonist effect.
The antibody was conjugated to an oligonucleotide that contains an antibody clone-specific barcode (ABC) flanked by a poly-A tail on the 3' end and a PCR handle (PCR primer binding site) on the 5' end. The ABC for this antibody was designed to be used with other BD AbSeq oligonucleotides conjugated to other antibodies. All AbSeq ABC sequences were selected in silico to be unique from human and mouse genomes, have low predicted secondary structure, and have high Hamming distance within the BD AbSeq portfolio, to allow for sequencing error correction and unique mapping. The poly-A tail of the oligonucleotide allows the ABC to be captured by the BD Rhapsody™ system. The 5' PCR handle allows for efficient sequencing library generation for Illumina sequencing platforms.
NOTE: The BD Rhapsody Single-Cell Analysis System must be used with the BD Rhapsody Express Instrument.